These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 25311879

  • 1. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
    Sharma R, Seth A, Chandra J, Gohain S, Kapoor S, Singh P, Pemde H.
    Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
    [Abstract] [Full Text] [Related]

  • 2. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Feb; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 3. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT, Yassin MA, De Sanctis V.
    Acta Biomed; 2018 Feb 16; 89(2-S):27-32. PubMed ID: 29451226
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, Terlizzi F, Guitarrini MR, Monti S, Maffei L, Losardo A, Pasin M, Toscano V.
    Ann Hematol; 2016 Apr 16; 95(5):757-63. PubMed ID: 26957357
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct 16; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 16; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V, Eleftheriou A, Malaventura C, Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia.
    Pediatr Endocrinol Rev; 2004 Dec 16; 2 Suppl 2():249-55. PubMed ID: 16462705
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 16; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 14. Low bone mineral density in adolescents with beta-thalassemia.
    Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ.
    Ann N Y Acad Sci; 2005 Aug 13; 1054():462-6. PubMed ID: 16339698
    [Abstract] [Full Text] [Related]

  • 15. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT.
    Ann Hematol; 2012 Jul 13; 91(7):1107-14. PubMed ID: 22281991
    [Abstract] [Full Text] [Related]

  • 16. Growth and management of short stature in thalassaemia major.
    Theodoridis C, Ladis V, Papatheodorou A, Berdousi H, Palamidou F, Evagelopoulou C, Athanassaki K, Konstantoura O, Kattamis C.
    J Pediatr Endocrinol Metab; 1998 Jul 13; 11 Suppl 3():835-44. PubMed ID: 10091154
    [Abstract] [Full Text] [Related]

  • 17. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 18. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb 10; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 19. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A, Amendola G, Pugliese U, Tartaglione I, Della Rocca F, Cinque P, Nobili B, Perrotta S.
    Am J Hematol; 2014 Dec 10; 89(12):1102-6. PubMed ID: 25197009
    [Abstract] [Full Text] [Related]

  • 20. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
    Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G.
    Br J Haematol; 2006 Aug 10; 134(4):438-44. PubMed ID: 16822284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.